Identification
ISIN code
FR0010915553
Exchange / Market
Euronext
Trading location
Paris
ICB
Pharmaceuticals
Activity description

<p>
Created in 2000, Novagali Pharma develops a broad portfolio of innovative ophthalmic products addressing the numerous needs of patients suffering from ocular conditions.Its core area of expertise is in the formulation and development of ophthalmic products.<br />
<br />
Novagali Pharma products pipeline includes major products at various stages of development, which address the most important diseases encountered at the three different segment levels of the eye (surface, anterior and posterior segments) such as dry eye, allergy, glaucoma, retinopathies, etc. Their formulations are based on its proprietary technology platforms Novasorb&reg; and Eyeject&reg;, which optimize bioavailability of drugs as well as safety and comfort for the patient.</p>

Issuer website
http://www.novagali.com
Operation
IPO date
IPO type

<p>
Public Offering</p>

IPO type
Initial Public offering
Catégorie
IPO